Top Tweets for #MevPro
#MEVPRO-3: Phase III trial of mevrometostat + enzalutamide vs placebo + enzalutamide in #mCSPC. Presentation by @neerajaiims @huntsmancancer. #GU26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/yWz8Sm9S1Q @ASCO #ASCOGU26
Trials-in-progress: Mevrometostat in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-naïve patients with #mCRPC: The phase 3, randomized #MEVPRO-2 study. Presentation by Neal Shore, MD, FACS @CURCMB. #ASCO25 written coverage by @RKSayyid @USC > https://t.co/vnzJSIHF07 @ASCO
Mevrometostat in combination with enzalutamide in patients with #mCRPC previously treated with abiraterone acetate: The phase 3, randomized #MEVPRO-1 study. Presentation by @neerajaiims @huntsmancancer. #ASCO25 written coverage by @chavarriagaj @UofT > https://t.co/9xDZWCDAAm @ASCO
Combining EZH2 and AR targeting in metastatic castration-resistant #ProstateCancer. @neerajaiims @huntsmancancer joins @zklaassen_md @GACancerCenter to discuss the #MEVPRO-1 study examining mevrometostat in combination with enzalutamide for #mCRPC patients previously treated with abiraterone acetate. #WatchNow on UroToday > https://t.co/akUfXDqGam
Combining EZH2 and AR targeting in metastatic castration-resistant #ProstateCancer. @neerajaiims @huntsmancancer joins @zklaassen_md @GACancerCenter to discuss the #MEVPRO-1 study examining mevrometostat in combination with enzalutamide for #mCRPC patients previously treated with abiraterone acetate. #WatchNow on UroToday > https://t.co/akUfXDqGam
Combining EZH2 and AR targeting in metastatic castration-resistant #ProstateCancer. @neerajaiims @huntsmancancer joins @zklaassen_md @GACancerCenter to discuss the #MEVPRO-1 study examining mevrometostat in combination with enzalutamide for #mCRPC patients previously treated with abiraterone acetate. #WatchNow on UroToday > https://t.co/akUfXDqGam
Combining EZH2 and AR targeting in metastatic castration-resistant #ProstateCancer. @neerajaiims @huntsmancancer joins @zklaassen_md @GACancerCenter to discuss the #MEVPRO-1 study examining mevrometostat in combination with enzalutamide for #mCRPC patients previously treated with abiraterone acetate. #WatchNow on UroToday > https://t.co/akUfXDqGam
Combining EZH2 and AR targeting in metastatic castration-resistant #ProstateCancer. @neerajaiims @huntsmancancer joins @zklaassen_md @GACancerCenter to discuss the #MEVPRO-1 study examining mevrometostat in combination with enzalutamide for #mCRPC patients previously treated with abiraterone acetate. #WatchNow on UroToday > https://t.co/akUfXDqGam
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
240.7M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
111M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91M followers
KATY PERRY
@katyperry
87.8M followers
Taylor Swift
@taylorswift13
81.7M followers
Lady Gaga
@ladygaga
73.2M followers
Virat Kohli
@imvkohli
70.2M followers
Kim Kardashian
@kimkardashian
69.9M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64M followers
Neymar Jr
@neymarjr
63M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
60.9M followers
X
@x
60.8M followers